Once-daily Topical Treatment for Psoriasis: Calcipotriene + Betamethasone Two-compound Topical Formulation

Overview

Journal Clin Cosmet Investig Dermatol

Publisher Dove Medical Press

Specialty Dermatology

Date 2014 Jan 1

PMID 24379688

Citations 2

Authors

Jonisha Shepherd

Arash Taheri

Steven R Feldman

Affiliations

Soon will be listed here.

Abstract

Background: Topical treatments are usually effective in mild psoriasis. However, the complexity of their use may result in low patient adherence with treatment. Combination of a vitamin D analog and a corticosteroid into a two-compound topical formulation has increased efficacy compared with either drug administered alone. Once-daily application of such a product would likely improve adherence. The purpose of this study was to determine whether twice-daily application of a calcipotriene + betamethasone topical formulation can provide improved clinical outcomes compared with once-daily treatment with the same product.

Methods: A review of the literature was performed seeking clinical trials comparing once-daily versus twice-daily application of calcipotriene + betamethasone topical formulations for the treatment of psoriasis.

Results: We found only one relevant clinical trial. This study showed similar efficacy and safety with once-daily versus twice-daily application of a topical calcipotriene + betamethasone formulation in the treatment of psoriasis vulgaris.

Conclusion: Once-daily application of a topical calcipotriene + betamethasone formulation may offer increased patient convenience and potentially increased patient adherence with long-term treatment, compared with twice-daily use, without reducing the efficacy. In order to enhance adherence, patient preference regarding frequency of application of topical treatments should be considered when prescribing medications.

Citing Articles

Calcipotriol/betamethasone for the treatment of psoriasis: efficacy, safety, and patient acceptability.

Rogalski C Psoriasis (Auckl). 2018; 5:97-107.

PMID: 29387586 PMC: 5683117. DOI: 10.2147/PTT.S63127.

Adolescent Scalp Psoriasis: Update on Topical Combination Therapy.

Osier E, Gomez B, Eichenfield L J Clin Aesthet Dermatol. 2015; 8(7):43-7.

PMID: 26203320 PMC: 4509585.

References

Kragballe K, Austad J, Barnes L, Bibby A, De La Brassinne M, Cambazard F . A 52-week randomized safety study of a calcipotriol/betamethasone dipropionate two-compound product (Dovobet/Daivobet/Taclonex) in the treatment of psoriasis vulgaris. Br J Dermatol. 2006; 154(6):1155-60. DOI: 10.1111/j.1365-2133.2006.07236.x. View

van de Kerkhof P, de Peuter R, Ryttov J, Jansen J . Mixed treatment comparison of a two-compound formulation (TCF) product containing calcipotriol and betamethasone dipropionate with other topical treatments in psoriasis vulgaris. Curr Med Res Opin. 2010; 27(1):225-38. DOI: 10.1185/03007995.2010.541005. View

Vissers W, Berends M, Muys L, van Erp P, de Jong E, van de Kerkhof P . The effect of the combination of calcipotriol and betamethasone dipropionate versus both monotherapies on epidermal proliferation, keratinization and T-cell subsets in chronic plaque psoriasis. Exp Dermatol. 2004; 13(2):106-12. DOI: 10.1111/j.0906-6705.2004.00151.x. View

Cassano N, Miracapillo A, Coviello C, Loconsole F, Bellino M, Vena G . Treatment of psoriasis vulgaris with the two-compound product calcipotriol/betamethasone dipropionate followed by different formulations of calcipotriol. Clin Drug Investig. 2006; 26(4):227-33. DOI: 10.2165/00044011-200626040-00008. View

van de Kerkhof P . The impact of a two-compound product containing calcipotriol and betamethasone dipropionate (Daivobet/ Dovobet) on the quality of life in patients with psoriasis vulgaris: a randomized controlled trial. Br J Dermatol. 2004; 151(3):663-8. DOI: 10.1111/j.1365-2133.2004.06134.x. View

Yentzer B, Ade R, Fountain J, Clark A, Taylor S, Fleischer Jr A . Simplifying regimens promotes greater adherence and outcomes with topical acne medications: a randomized controlled trial. Cutis. 2010; 86(2):103-8. View

Douglas W, Poulin Y, Decroix J, Ortonne J, Mrowietz U, Gulliver W . A new calcipotriol/betamethasone formulation with rapid onset of action was superior to monotherapy with betamethasone dipropionate or calcipotriol in psoriasis vulgaris. Acta Derm Venereol. 2002; 82(2):131-5. DOI: 10.1080/00015550252948194. View

Menter A, Abramovits W, Colon L, Johnson L, Gottschalk R . Comparing clobetasol propionate 0.05% spray to calcipotriene 0.005% betamethasone dipropionate 0.064% ointment for the treatment of moderate to severe plaque psoriasis. J Drugs Dermatol. 2009; 8(1):52-7. View

van de Kerkhof P, Hoffmann V, Anstey A, Barnes L, Bolduc C, Reich K . A new scalp formulation of calcipotriol plus betamethasone dipropionate compared with each of its active ingredients in the same vehicle for the treatment of scalp psoriasis: a randomized, double-blind, controlled trial. Br J Dermatol. 2008; 160(1):170-6. DOI: 10.1111/j.1365-2133.2008.08927.x. View

10.

Saraceno R, Andreassi L, Ayala F, Bongiorno M, Giannetti A, Lisi P . Efficacy, safety and quality of life of calcipotriol/betamethasone dipropionate (Dovobet) versus calcipotriol (Daivonex) in the treatment of psoriasis vulgaris: a randomized, multicentre, clinical trial. J Dermatolog Treat. 2007; 18(6):361-5. DOI: 10.1080/09546630701646156. View

11.

Barna M, Bos J, Kapsenberg M, Snijdewint F . Effect of calcitriol on the production of T-cell-derived cytokines in psoriasis. Br J Dermatol. 1997; 136(4):536-41. View

12.

Guenther L, van de Kerkhof P, Snellman E, Kragballe K, Chu A, Tegner E . Efficacy and safety of a new combination of calcipotriol and betamethasone dipropionate (once or twice daily) compared to calcipotriol (twice daily) in the treatment of psoriasis vulgaris: a randomized, double-blind, vehicle-controlled clinical trial. Br J Dermatol. 2002; 147(2):316-23. DOI: 10.1046/j.1365-2133.2002.04967.x. View

13.

Tyring S, Mendoza N, Appell M, Bibby A, Foster R, Hamilton T . A calcipotriene/betamethasone dipropionate two-compound scalp formulation in the treatment of scalp psoriasis in Hispanic/Latino and Black/African American patients: results of the randomized, 8-week, double-blind phase of a clinical trial. Int J Dermatol. 2010; 49(11):1328-33. DOI: 10.1111/j.1365-4632.2010.04598.x. View

14.

Rigopoulos D, Gregoriou S, Daniel Iii C, Belyayeva H, Larios G, Verra P . Treatment of nail psoriasis with a two-compound formulation of calcipotriol plus betamethasone dipropionate ointment. Dermatology. 2009; 218(4):338-41. DOI: 10.1159/000202179. View

15.

Jemec G, Ganslandt C, Ortonne J, Poulin Y, Burden A, de Unamuno P . A new scalp formulation of calcipotriene plus betamethasone compared with its active ingredients and the vehicle in the treatment of scalp psoriasis: a randomized, double-blind, controlled trial. J Am Acad Dermatol. 2008; 59(3):455-63. DOI: 10.1016/j.jaad.2008.04.027. View

16.

Peeters P, Ortonne J, Sitbon R, Guignard E . Cost-effectiveness of once-daily treatment with calcipotriol/betamethasone dipropionate followed by calcipotriol alone compared with tacalcitol in the treatment of Psoriasis vulgaris. Dermatology. 2005; 211(2):139-45. DOI: 10.1159/000086444. View

17.

Buckley C, Hoffmann V, Shapiro J, Saari S, Cambazard F, Milsgaard M . Calcipotriol plus betamethasone dipropionate scalp formulation is effective and well tolerated in the treatment of scalp psoriasis: a phase II study. Dermatology. 2008; 217(2):107-13. DOI: 10.1159/000130425. View

18.

Kanzler M, Chui C, Gorsulowsky D . Once-daily vs twice-daily triamcinolone acetonide cream for psoriasis. Arch Dermatol. 2001; 137(11):1529-32. View

19.

Menter A, Gold L, Bukhalo M, Grekin S, Kempers S, Boyce B . Calcipotriene plus betamethasone dipropionate topical suspension for the treatment of mild to moderate psoriasis vulgaris on the body: a randomized, double-blind, vehicle-controlled trial. J Drugs Dermatol. 2013; 12(1):92-8. View

20.

Fleming C, Ganslandt C, Guenther L, Johannesson A, Buckley C, Simon J . Calcipotriol plus betamethasone dipropionate gel compared with its active components in the same vehicle and the vehicle alone in the treatment of psoriasis vulgaris: a randomised, parallel group, double-blind, exploratory study. Eur J Dermatol. 2010; 20(4):465-71. DOI: 10.1684/ejd.2010.0948. View